Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | Alliance A071601 |
---|---|
Cancer Type: | CRANIOPHARYNGIOMAS |
Fast Facts |
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | NRG BN007 |
---|---|
Cancer Type: | Unmethylated Glioblastoma |
Fast Facts |
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Protocol | Alliance A071702 |
---|---|
Cancer Type: | Recurrent Glioblastoma |
Fast Facts |
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | N0577 |
---|---|
Cancer Type: | Codeleted Anaplastic Glioma |
Fast Facts |
Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071401 |
---|---|
Cancer Type: | MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS |
Fast Facts |
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Protocol | NRG BN003 |
---|---|
Cancer Type: | MENINGIOMA |
Fast Facts |
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A071701 |
---|---|
Cancer Type: | Brain metastases |
Fast Facts |
Genomically-Guided Treatment Trial in Brain Metastases
Protocol | Alliance A071801 |
---|---|
Cancer Type: | Metastatic Brain Disease |
Fast Facts |
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | ACCRU 2018-01 |
---|---|
Cancer Type: | Untreated Solid Tumors |
Fast Facts |
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors
Protocol | WF 1801 |
---|---|
Cancer Type: | Cancer Control |
Fast Facts |
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ACNS1422 |
---|---|
Cancer Type: | Medulloblastoma |
Fast Facts |
A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.
Protocol | COG ACNS1721 |
---|---|
Cancer Type: | High-Grade Glioma |
Fast Facts |
A Phase II Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation,Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.
Patients >21 Years must be IDH Mutant.
Note: At the time of ACNS1721 Step 1 enrollment, patients will be stratified and age is a factor.
Protocol | COG ACNS1723 |
---|---|
Cancer Type: | High-Grade Glioma |
Fast Facts |
A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.
Protocol | COG ACNS1831 |
---|---|
Cancer Type: | Low-Grade Glioma |
Fast Facts |
A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.
Protocol | COG ACNS1833 |
---|---|
Cancer Type: | Low-Grade Glioma |
Fast Facts |
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.
Protocol | COG ANBL00B1 |
---|---|
Cancer Type: | Neuroblastoma-Biology |
Fast Facts |
Neuroblastoma Biology Studies
All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study.
Protocol | COG-ACNS1931 |
---|---|
Cancer Type: | Low Grade Glioma |
Fast Facts |
COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.